Literature DB >> 34547463

Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary.

Jill A Morris1, Chris H Boshoff2, Nina F Schor2, Ling M Wong2, Guangping Gao3, Beverly L Davidson4.   

Abstract

The National Institute of Neurological Disorders and Stroke (NINDS) held a workshop titled "Next generation strategies for gene-targeted therapies of central nervous system (CNS) disorders" in September 2019 in Bethesda, MD, USA. The meeting brought together a multi-disciplinary group of experts in the field of CNS-directed gene-targeted therapy delivery from academia, industry, advocacy, and the government. The group was charged with identifying the key challenges and gaps in this evolving field, as well as suggesting potential solutions. The workshop was divided into four sessions: (1) control of level and location, (2) improving delivery and distribution, (3) enhancing models and manufacturing, and (4) impacting patients. Prior to the workshop, NINDS established working groups of key opinion leaders (KOLs) for each session. In pre-meeting teleconferences, KOLs were tasked with identifying the research gaps and key obstacles that delay and/or prevent gene-targeted therapies to move into the clinic. This approach allowed for the workshop to begin with problem-solving discussions and strategy development, as the key issues had been established. The overall purpose of the workshop was to consider knowledge gaps and potential strategies to inform the community around CNS gene-targeted therapies, including but not limited to researchers and funders.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV vectors; antisense oligonucleotides; central nervous system; gene-targeted therapies; ultra-rare diseases

Mesh:

Year:  2021        PMID: 34547463      PMCID: PMC8636163          DOI: 10.1016/j.ymthe.2021.09.010

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state.

Authors:  Brian D Brown; Bernhard Gentner; Alessio Cantore; Silvia Colleoni; Mario Amendola; Anna Zingale; Alessia Baccarini; Giovanna Lazzari; Cesare Galli; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2007-11-16       Impact factor: 54.908

2.  Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity.

Authors:  Yuanyuan Xiao; Manish Muhuri; Shaoyong Li; Wanru Qin; Guangchao Xu; Li Luo; Jia Li; Alexander J Letizia; Sean K Wang; Ying Kai Chan; Chunmei Wang; Sebastian P Fuchs; Dan Wang; Qin Su; M Abu Nahid; George M Church; Michael Farzan; Li Yang; Yuquan Wei; Ronald C Desrosiers; Christian Mueller; Phillip Wl Tai; Guangping Gao
Journal:  JCI Insight       Date:  2019-05-21

3.  The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice.

Authors:  Juliette Hordeaux; Qiang Wang; Nathan Katz; Elizabeth L Buza; Peter Bell; James M Wilson
Journal:  Mol Ther       Date:  2018-02-02       Impact factor: 11.454

4.  Adeno-Associated Virus Serotype-Specific Inverted Terminal Repeat Sequence Role in Vector Transgene Expression.

Authors:  Lauriel F Earley; Laura M Conatser; Victoria M Lue; Amanda L Dobbins; Chengwen Li; Matthew L Hirsch; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2020-02       Impact factor: 5.695

5.  Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.

Authors:  Diane Golebiowski; Imramsjah M J van der Bom; Churl-Su Kwon; Andrew D Miller; Keiko Petrosky; Allison M Bradbury; Stacy Maitland; Anna Luisa Kühn; Nina Bishop; Elizabeth Curran; Nilsa Silva; Dwijit GuhaSarkar; Susan V Westmoreland; Douglas R Martin; Matthew J Gounis; Wael F Asaad; Miguel Sena-Esteves
Journal:  Hum Gene Ther       Date:  2017-01-26       Impact factor: 5.695

6.  Mouse strains with typical mammalian levels of complement activity.

Authors:  G L Ong; M J Mattes
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

7.  AAV vector integration sites in mouse hepatocellular carcinoma.

Authors:  Anthony Donsante; Daniel G Miller; Yi Li; Carole Vogler; Elizabeth M Brunt; David W Russell; Mark S Sands
Journal:  Science       Date:  2007-07-27       Impact factor: 47.728

8.  High levels of AAV vector integration into CRISPR-induced DNA breaks.

Authors:  Killian S Hanlon; Benjamin P Kleinstiver; Sara P Garcia; Mikołaj P Zaborowski; Adrienn Volak; Stefan E Spirig; Alissa Muller; Alexander A Sousa; Shengdar Q Tsai; Niclas E Bengtsson; Camilla Lööv; Martin Ingelsson; Jeffrey S Chamberlain; David P Corey; Martin J Aryee; J Keith Joung; Xandra O Breakefield; Casey A Maguire; Bence György
Journal:  Nat Commun       Date:  2019-09-30       Impact factor: 17.694

9.  Regulated control of gene therapies by drug-induced splicing.

Authors:  Alex Mas Monteys; Amiel A Hundley; Paul T Ranum; Luis Tecedor; Amy Muehlmatt; Euyn Lim; Dmitriy Lukashev; Rajeev Sivasankaran; Beverly L Davidson
Journal:  Nature       Date:  2021-07-28       Impact factor: 49.962

View more
  3 in total

Review 1.  Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders.

Authors:  Beverly L Davidson; Guangping Gao; Elizabeth Berry-Kravis; Allison M Bradbury; Carsten Bönnemann; Joseph D Buxbaum; Gavin R Corcoran; Steven J Gray; Heather Gray-Edwards; Robin J Kleiman; Adam J Shaywitz; Dan Wang; Huda Y Zoghbi; Terence R Flotte; Sitra Tauscher-Wisniewski; Cynthia J Tifft; Mustafa Sahin
Journal:  Mol Ther       Date:  2022-05-17       Impact factor: 12.910

2.  Molecular Signatures of Mitochondrial Complexes Involved in Alzheimer's Disease via Oxidative Phosphorylation and Retrograde Endocannabinoid Signaling Pathways.

Authors:  Fenqin Chen; Jun Bai; Shanshan Zhong; Rongwei Zhang; Xiaoqian Zhang; Ying Xu; Mei Zhao; Chuansheng Zhao; Zhike Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-04-05       Impact factor: 6.543

Review 3.  GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy.

Authors:  Maya Chopra; Meera E Modi; Kira A Dies; Nancy L Chamberlin; Elizabeth D Buttermore; Stephanie Jo Brewster; Lisa Prock; Mustafa Sahin
Journal:  Mol Ther Methods Clin Dev       Date:  2022-08-29       Impact factor: 5.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.